Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2021

View Archived Issues

Neurons increase cholesterol synthesis during chronic myelin disease

ALP and LECT2 are markers of SZN-043 target engagement and Wnt pathway activation

In vivo studies of HRX-0215 in acute and chronic liver disease

LINC01348 as a potential new therapeutic target and biomarker in HCC

NTX-1088, anti-PVR MAb with exclusive triple mechanism of action

Fochon Pharmaceuticals patents Bcl-2 inhibitors

Eli Lilly patents new Ret inhibitors

Janssen Pharmaceutica synthesizes new IL-17A/IL-17RA interaction modulators

Recurium IP Holdings presents new PROTACs for cancer

U.S. researchers divulge new PI3K-alpha inhibitors

AL-009 shows antitumor efficacy both as monotherapy and in combination with anti-PD-L1

Potent non-HAP class I HBV capsid assembly modulator ALG-005398 reduces HBsAg levels in vivo

One-year challenge data from preclinical study of ATI-1701 in lethal model of tularemia

BTT-105 ameliorates hepatic fibrosis in NAFLD animal model

Simcere and SIMM collaborate to develop novel oral antivirals for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.